HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 4 matching records:

Displaying record number 58812

HXB2 Location  Gag(147-155)   Gag Epitope Map
View variants at this location
Epitope ISPRTLNAW   Epitope Alignment
Variants
{s}lSPRTLNAW   observed variant
{p}lSPRTLNAW   observed variant
lSPRTLNAW   observed variant
{p}ISPRTLNAW   observed variant
{p}IaPRTLNAW   observed variant
{p}ItPRTLNAW   observed variant
{p}ltPRTLNAW   observed variant
ItPRTLNAW   observed variant
IlPRTLNAW   observed variant
Epitope Name ISW9
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 9 variant(s).


Variant ID.  3172
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {s}lSPRTLNAW
Mutations A/S I/L
Epitope Location A-1S I1L
HXB2 Location A145S I146L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {s}lSPRTLNAW{V}, were seen for ISW9 by 13 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701.


Variant ID.  3173
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}lSPRTLNAW
Mutations A/P I/L
Epitope Location A-1P I1L
HXB2 Location A145P I146L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {p}lSPRTLNAW{V}, were seen for ISW9 by 104 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701 and at 179 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701.


Variant ID.  3174
Epitope Seq.  ISPRTLNAW
Variant Seq.  lSPRTLNAW
Mutations I/L
Epitope Location I1L
HXB2 Location I146L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, A|lSPRTLNAW|V, was seen for ISW9 by 271 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701; at 45 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701; from 144 weeks post-infection in patient 5 (P5) who carried alleles A*0101,A*0101,B*0801,B*5701 and from 17 weeks post-infection in patient 6 (P6) who carried alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3175
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}ISPRTLNAW
Mutations A/P
Epitope Location A-1P
HXB2 Location A145P
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking mutation, {p}ISPRTLNAW{V}, was seen for ISW9 from 75 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701; from 60 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701; and from 10 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3176
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}IaPRTLNAW
Mutations A/P S/A
Epitope Location A-1P S2A
HXB2 Location A145P S147A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {p}IaPRTLNAW{V}, were seen for ISW9 by 274 weeks post-infection in P3 who carried HLA alleles A*2402 , A*3201, B*4002, B*5701.


Variant ID.  3177
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}ItPRTLNAW
Mutations A/P S/T
Epitope Location A-1P S2T
HXB2 Location A145P S147T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {p}ItPRTLNAW{V}, were seen for ISW9 by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.


Variant ID.  3178
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}ltPRTLNAW
Mutations A/P I/L S/T
Epitope Location A-1P I1L S2T
HXB2 Location A145P I146L S147T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, {A}ItPRTLNAW{V}, was seen for ISW9 by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.


Variant ID.  3179
Epitope Seq.  ISPRTLNAW
Variant Seq.  ItPRTLNAW
Mutations S/T
Epitope Location S2T
HXB2 Location S147T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, A|ItPRTLNAW|V, were seen for ISW9 by 316 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.


Variant ID.  3180
Epitope Seq.  ISPRTLNAW
Variant Seq.  IlPRTLNAW
Mutations S/L
Epitope Location S2L
HXB2 Location S147L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations including IlPRTLNAW, were seen for ISW9 by 45 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.

References

Norstrom2012 Melissa M. Norström, Marcus Buggert, Johanna Tauriainen, Wendy Hartogensis, Mattia C. Prosperi, Mark A. Wallet, Frederick M. Hecht, Marco Salemi, and Annika C. Karlsson. Combination of Immune and Viral Factors Distinguishes Low-Risk Versus High-Risk HIV-1 Disease Progression in HLA-B*5701 Subjects. J. Virol., 86(18):9802-9816, Sep 2012. PubMed ID: 22761389. Show all entries for this paper.


Displaying record number 58840

HXB2 Location  Gag(162-172)   Gag Epitope Map
View variants at this location
Epitope KAFSPEVIPMF   Epitope Alignment
Variants
KAFSPEVIPMs   observed variant
KAFSPEVIPMt   observed variant
KAFSPEiIPMF   observed variant
KAsSPEVIPMF   observed variant
Epitope Name KF11
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 4 variant(s).


Variant ID.  3181
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEVIPMs
Mutations F/S
Epitope Location F11S
HXB2 Location F171S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Epitope mutation, E|KAFSPEVIPMs|S, was seen for KF11 by 104 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.


Variant ID.  3182
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEVIPMt
Mutations F/T
Epitope Location F11T
HXB2 Location F171T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Epitope mutation, E|KAFSPEVIPMt|S, was seen for KF11 by 168 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701 and by 377 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3183
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEiIPMF
Mutations V/I
Epitope Location V7I
HXB2 Location V167I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Epitope mutation, E|KAFSPEiIPMF|S, was seen for KF11 by 168 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701 and by 301 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3184
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAsSPEVIPMF
Mutations F/S
Epitope Location F3S
HXB2 Location F163S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Epitope mutation, E|KAFSPEVIPMF|S, was seen for KF11 by 301 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.

References

Norstrom2012 Melissa M. Norström, Marcus Buggert, Johanna Tauriainen, Wendy Hartogensis, Mattia C. Prosperi, Mark A. Wallet, Frederick M. Hecht, Marco Salemi, and Annika C. Karlsson. Combination of Immune and Viral Factors Distinguishes Low-Risk Versus High-Risk HIV-1 Disease Progression in HLA-B*5701 Subjects. J. Virol., 86(18):9802-9816, Sep 2012. PubMed ID: 22761389. Show all entries for this paper.


Displaying record number 58842

HXB2 Location  Gag(240-249)   Gag Epitope Map
View variants at this location
Epitope TSTLQEQIGW   Epitope Alignment
Variants
TSTLrEQIGW   observed variant
TSTLQEQIeW   observed variant
TSnLQEQIGW   observed variant
TSsLQEQIGW   observed variant
TSnLQEQIrW   observed variant
TSnLQEQIaW   observed variant
TSnLQEQItW   observed variant
TSTLQEQIaW   observed variant
Epitope Name TW10
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 8 variant(s).


Variant ID.  3188
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSTLrEQIGW
Mutations Q/R
Epitope Location Q5R
HXB2 Location Q243R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, T|TSTLrEQIGW|M, was seen for TW10 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.


Variant ID.  3189
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSTLQEQIeW
Mutations G/E
Epitope Location G9E
HXB2 Location G247E
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, T|TSTLQEQIeW|M, was seen for TW10 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701 and at 13 weeks post-infection in P5 who carried HLA alleles A*0101,A*0101,B*0801,B*5701.


Variant ID.  3190
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSnLQEQIGW
Mutations T/N
Epitope Location T3N
HXB2 Location T241N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Most common epitope mutation, T|TSnLQEQIGW|M, was seen for TW10 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701; by 18 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*5701; by 13 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701; by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701 and by 10 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3192
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSsLQEQIGW
Mutations T/S
Epitope Location T3S
HXB2 Location T241S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, T|TSsLQEQIGW|M, was seen for TW10 by the first sampling 18 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*570.


Variant ID.  3193
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSnLQEQIrW
Mutations T/N G/R
Epitope Location T3N G9R
HXB2 Location T241N G247R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Most common epitope mutation, T|TSnLQEQIrW|M, was seen for TW10 by 109 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.


Variant ID.  3194
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSnLQEQIaW
Mutations T/N G/A
Epitope Location T3N G9A
HXB2 Location T241N G247A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Most common epitope mutation, T|TSnLQEQIaW|M, was seen for TW10 by 45 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701; by 11 weeks post-infection in P4 who carried the HLA alleles A*0101,A*0201,B*5101,B*5701; and by 144 weeks post-infection in P5 who carried the HLA alleles A*0101,A*0101,B*0801,B*5701.


Variant ID.  3195
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSnLQEQItW
Mutations T/N G/R
Epitope Location T3N G9R
HXB2 Location T241N G247R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Most common epitope mutation, T|TSnLQEQIrW|M, was seen for TW10 by 195 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.


Variant ID.  3196
Epitope Seq.  TSTLQEQIGW
Variant Seq.  TSTLQEQIaW
Mutations G/A
Epitope Location G9A
HXB2 Location G247A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Most common epitope mutation, T|TSTLQEQIaW|M, was seen for TW10 by 13 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.

References

Norstrom2012 Melissa M. Norström, Marcus Buggert, Johanna Tauriainen, Wendy Hartogensis, Mattia C. Prosperi, Mark A. Wallet, Frederick M. Hecht, Marco Salemi, and Annika C. Karlsson. Combination of Immune and Viral Factors Distinguishes Low-Risk Versus High-Risk HIV-1 Disease Progression in HLA-B*5701 Subjects. J. Virol., 86(18):9802-9816, Sep 2012. PubMed ID: 22761389. Show all entries for this paper.


Displaying record number 58841

HXB2 Location  Gag(308-316)   Gag Epitope Map
View variants at this location
Epitope QASQEVKNW   Epitope Alignment
Variants
QASQdVKNW   observed variant
QASQtVKNW   observed variant
QASkEVKNW   observed variant
Epitope Name QW9
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 3 variant(s).


Variant ID.  3185
Epitope Seq.  QASQEVKNW
Variant Seq.  QASQdVKNW
Mutations E/D
Epitope Location E5D
HXB2 Location E311D
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Epitope mutation, E|QASQdVKNW|M, was seen for QW9 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701; and by 75 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.


Variant ID.  3186
Epitope Seq.  QASQEVKNW
Variant Seq.  QASQtVKNW
Mutations E/T
Epitope Location E5T
HXB2 Location E311T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Epitope mutation E312T, E|QASQtVKNW|M, was seen for QW9 by the first sampling 18 weeks post-infection in P2 who carried HLA alleles A*0101,A*2402,B*4002,B*5701.


Variant ID.  3187
Epitope Seq.  QASQEVKNW
Variant Seq.  QASkEVKNW
Mutations Q/K
Epitope Location Q4K
HXB2 Location Q310K
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Flow cytometric T-cell cytokine assay
Note Minor (4.5%) epitope variation E312K, E|QASkEVKNW|M, was seen for QW9 at 60 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.

References

Norstrom2012 Melissa M. Norström, Marcus Buggert, Johanna Tauriainen, Wendy Hartogensis, Mattia C. Prosperi, Mark A. Wallet, Frederick M. Hecht, Marco Salemi, and Annika C. Karlsson. Combination of Immune and Viral Factors Distinguishes Low-Risk Versus High-Risk HIV-1 Disease Progression in HLA-B*5701 Subjects. J. Virol., 86(18):9802-9816, Sep 2012. PubMed ID: 22761389. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health